Greenwich LifeSciences, Inc. beat EPS estimates 50% of the time across 2 reported quarters (1 beats, 1 misses), averaging +0.0% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.33 | $-0.27 | +18.2% | Beat | |
| Q1 FY26 | $-0.33 | $-0.39 | -18.2% | Miss |
Back to GLSI overview · GLSI holders · GLSI KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.